234 related articles for article (PubMed ID: 12901961)
1. Neuroblastoma: biology and molecular and chromosomal pathology.
Schwab M; Westermann F; Hero B; Berthold F
Lancet Oncol; 2003 Aug; 4(8):472-80. PubMed ID: 12901961
[TBL] [Abstract][Full Text] [Related]
2. Molecular biology of neuroblastoma.
Castel V; Grau E; Noguera R; Martínez F
Clin Transl Oncol; 2007 Aug; 9(8):478-83. PubMed ID: 17720650
[TBL] [Abstract][Full Text] [Related]
3. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
[TBL] [Abstract][Full Text] [Related]
4. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
[TBL] [Abstract][Full Text] [Related]
5. Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.
Aygun N
Curr Pediatr Rev; 2018; 14(2):73-90. PubMed ID: 29380702
[TBL] [Abstract][Full Text] [Related]
6. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted.
Caron H; Spieker N; Godfried M; Veenstra M; van Sluis P; de Kraker J; Voûte P; Versteeg R
Genes Chromosomes Cancer; 2001 Feb; 30(2):168-74. PubMed ID: 11135433
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene.
Ejeskär K; Aburatani H; Abrahamsson J; Kogner P; Martinsson T
Br J Cancer; 1998 Jun; 77(11):1787-91. PubMed ID: 9667647
[TBL] [Abstract][Full Text] [Related]
9. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of molecular markers in neuroblastoma: results from a single institution.
Gallego S; Parareda A; Munell F; Sanchez de Toledo J; Reventos J
Oncol Rep; 1999; 6(4):891-6. PubMed ID: 10373677
[TBL] [Abstract][Full Text] [Related]
11. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma tumour genetics: clinical and biological aspects.
Bown N
J Clin Pathol; 2001 Dec; 54(12):897-910. PubMed ID: 11729208
[TBL] [Abstract][Full Text] [Related]
13. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
14. The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.
Tumer S; Altungoz O; Bagci O; Olgun HN
Genet Test Mol Biomarkers; 2016 Feb; 20(2):74-80. PubMed ID: 26790040
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
16. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
George RE; Variend S; Cullinane C; Cotterill SJ; McGuckin AG; Ellershaw C; Lunec J; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876
[TBL] [Abstract][Full Text] [Related]
17. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
18. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
[TBL] [Abstract][Full Text] [Related]
19. Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'.
van Noesel MM; Versteeg R
Gene; 2004 Jan; 325():1-15. PubMed ID: 14697505
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities.
Nakagawara A
Hum Cell; 1998 Sep; 11(3):115-24. PubMed ID: 10086274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
